Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe

Affiliations

¹ Biomedical Research and Training Institute, Harare, Zimbabwe; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: ioana-diana.olaru@lshtm.ac.uk.
² National Microbiology Reference Laboratory, Harare, Zimbabwe.
³ Department of Clinical Sciences, Liverpool School of Tropical medicine, Liverpool, UK; Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
⁴ Biomedical Research and Training Institute, Harare, Zimbabwe; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.

Comment

Ioana D Olaru et al. Lancet Infect Dis. 2019 Sep.

. 2019 Sep;19(9):930.

doi: 10.1016/S1473-3099(19)30425-6.

¹ Biomedical Research and Training Institute, Harare, Zimbabwe; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: ioana-diana.olaru@lshtm.ac.uk.
² National Microbiology Reference Laboratory, Harare, Zimbabwe.
³ Department of Clinical Sciences, Liverpool School of Tropical medicine, Liverpool, UK; Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
⁴ Biomedical Research and Training Institute, Harare, Zimbabwe; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.

No abstract available

Comment on

Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Bilcke J, et al. Lancet Infect Dis. 2019 Jul;19(7):728-739. doi: 10.1016/S1473-3099(18)30804-1. Epub 2019 May 23. Lancet Infect Dis. 2019. PMID: 31130329 Free PMC article.